The Port Washington-based specialty chemical company Aceto Corp. has named a new international senior vice president for active pharmaceutical ingredients.
He is Nicholas Shackley, a chemical engineer trained at the Imperial College of London, with a 25-year background in chemical and pharmaceutical sales and business development.
He comes to Aceto from BASF, where he was vice president-North America in the company's pharmaceutical ingredients unit.
"With our focus on accelerating growth in supplying quality ingredients for the pharmaceutical market on an international basis, we are delighted to have Nick join the company in this leadership role," chief executive Albert Eilender said in a prepared statement Monday.
"He is assuming responsibility for what has been a robust core activity for the company and we are anticipating that with his more expansive and diverse set of experiences, we will be able to enlarge our base of business in this most dynamic facet of the pharmaceutical markets."
Aceto said in June that it planned to shift its focus more closely on its own brand of generic pharmaceuticals to be sold under the Rising brand label.
Aceto bought Rising Pharmaceuticals Inc. in December. It is "a finished dosage form marketing and distribution company," the company said, and as such gives Aceto a channel for developing and marketing its own brand of generic pharmaceuticals -- the Rising brand.
On Aug. 4, Rising announced the introduction of one of its new generic drugs, 250 mg and 500 mg doses of Disulfirm tablets, which it said was "the first approved generic version of Teva's Antabuse tablets" for treatment of chronic alcoholism.